Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Extended phase 1 trial of combined metformin and erlotinib in advanced triple negative breast
cancer patients. The goals of the study are to establish the maximum tolerated combined
dosing of erlotinib and metformin as well as deciding if there is a potential clinical
utility of the combination in treating patients with triple negative breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Columbia University
Collaborators:
Astellas Pharma Inc Susan G. Komen Breast Cancer Foundation